Drug intelligence / Profile preview

Qingfeng Ganke

Development stage: Unknown
Lead developer: West China Hospital of Sichuan University
Administration: Oral

Overview

Qingfeng Ganke is a Traditional Chinese Medicine (TCM) formulation developed as granules for the treatment of postinfectious cough (PIC), specifically targeting the Wind-evil Loving Lung syndrome (风邪伏肺证). Developed by West China Hospital of Sichuan University, it is designed to alleviate persistent coughing that follows a respiratory tract infection. The formulation typically consists of multiple herbal ingredients aimed at clearing wind, ventilating the lungs, and relieving cough. It has been evaluated in Phase II clinical trials to assess its efficacy and safety compared to placebo in patients with postinfectious cough.

Brand names: Qingfeng Ganke Granules
Other names: Qingfeng Ganke Granules

Beyond the preview

Go deeper on Qingfeng Ganke.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingfeng Ganke.

Explore the full profile